Form 4: Vera Therapeutics CEO Marshall Fordyce Exercises Options and Sells Shares
SEC Form 4
Marshall Fordyce, CEO of Vera Therapeutics, exercised stock options and sold shares of Class A Common Stock on September 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 11, 2024, Marshall Fordyce, the President and CEO of Vera Therapeutics, exercised stock options to acquire 15,625 shares of Class A Common Stock at a price of $2.8968 per share.
- Simultaneously, Fordyce sold 15,625 shares of Class A Common Stock in the open market at weighted average prices of $37.3111 and $37.7753.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on April 23, 2024.
- Following these transactions, Fordyce directly owns 307,972 shares of Class A Common Stock and holds options for 827,337 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction under a pre-arranged plan, not indicative of any specific positive or negative outlook for the company.
Industry Context
This is a routine disclosure of insider trading activity. Executives often use 10b5-1 plans to diversify their holdings and avoid accusations of trading on inside information. The sale represents a small percentage of the CEO's overall holdings.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| December 16, 2021 | 1/4 of the shares subject to the option vested. |
| April 23, 2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan. |
| September 11, 2024 | Date of the transactions: exercising stock options and selling shares. |
| September 13, 2024 | Date of signature of the Form 4 filing. |
| December 15, 2030 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.